脂联素受体的表达与调节

脂联素受体1在骨骼肌中有丰富表达,而脂联素受体2主要在肝中表达。另外,两种脂联素受体也在胰岛β细胞、脂肪组织、单核细胞、巨噬细胞、成骨细胞、心肌组织和胎盘组织中表达。生长激素、胰岛素以及过氧化物酶体增殖物活化受体(PPAR)α、PPARγ和肝X受体激动剂等可影响脂联素受体的表达。研究脂联素受体在不同组织、细胞中的表达与调节可了解其组织特异性作用。     

胰岛素对大鼠骨骼肌细胞脂联素受体基因表达的影响

目的了解体外胰岛素对原代培养大鼠骨骼肌细胞脂联素受体1表达的影响。方法体外原代培养骨骼肌细胞,应用SYBRGreenⅠ染料建立一种快速、可靠的实时定量PCR,对其主要要素进行优化。观察不同胰岛素浓度不同作用时间下,大鼠骨骼肌细胞脂联素受体基因表达水平的动态变化。结果建立敏感、特异、快速检测脂联素受体1mRNA的实时定量PCR方法,随着胰岛素浓度的增加,脂联素受体1表达逐渐降低。在较低浓度（胰岛素浓度〈1nmol/L）时,脂联素受体1表达的降低无统计学意义,当胰岛素浓度增加到10nmol/L及以上时,骨骼肌细胞脂联素受体1表达的降低有统计学意义（P〈0.05）,这种抑制作用1h后出现,24h后达到高峰。结论成功地建立SYBRGreenⅠ实时定量PCR检测脂联素受体基因的表达方法,体外高胰岛素对骨骼肌细胞脂联素受体1mRNA表达有抑制作用,并呈时间和剂量依赖性。     

脂联素及其受体mRNA表达与血清游离脂肪酸、肿瘤坏死因子α的研究

目的 了解肿瘤坏死因子-α(TNF-α)和游离脂肪酸(FFA)与脂联素及脂联素受体mRNA表达的关系.方法 19例肥胖和29例正常体重受试者,采用RT-PCR检测腹部皮下与大网膜脂肪组织中脂联素及其受体mRNA的表达水平,同时测定血清脂联素、TNF-α、FFA等指标.结果 (1)肥胖患者的血清TNF-α、FFA高于正常体重组;脂联素降低.(2)肥胖组中网膜脂肪组织脂联素mRNA表达量低于皮下脂肪组织和正常体重组网膜脂肪组织.(3)网膜脂肪组织脂联素mRNA表达量与脂联素水平呈负相关.(4)腹部皮下脂肪组织的脂联素受体1、脂联素受体2 mRNA表达水平与血清脂联素、FFA呈负相关.结论 肥胖人群的血清TNF-α、FFA升高,脂联素降低,且其网膜脂肪组织中脂联素mRNA表达量亦降低;血清FFA升高与腹部皮下脂联素受体表达下调相关.     

NF-κB抑制剂对胰岛素抵抗大鼠抵抗素、脂联素和脂联素受体表达的影响

高脂喂养大鼠脂肪组织抵抗素、脂联素的表达均明显下降，加入N-乙酰半胱氨酸后脂联素表达增高，脂联素受体1表达无改变。抵抗素和脂联素水平的降低是高脂饲养大鼠体重增加、血糖升高、脂质代谢紊乱和胰岛素抵抗的重要原因。NF-κB通路介导了脂联素对胰岛素敏感性的调节作用，但不影响脂联素受体1的表达。     

脂联素受体及其与2型糖尿病的关系

人脂联素受体AdipoR1和AdipoR2均在骨骼肌丰富表达。且两者的表达呈正相关。而小鼠AdipoR1主要在骨骼肌中表达,AdipoR2则主要在肝脏表达。AdipoR1／R2的表达还受到多种因素的调节,包括胰岛素、生长激素等。此外,AdipoR1／R2在胰岛素抵抗、2型糖尿病的发生、发展中扮演了重要的角色。对脂联素受体研究的逐步深入,将加深对脂联素作用机制的了解,从而有助于2型糖尿病的预防和治疗。     

NF-kB抑制剂对胰岛素抵抗大鼠抵抗素、脂联素和脂联素受体表达的影响

高脂喂养大鼠脂肪组织抵抗素、脂联素的表达均明显下降,加入N-乙酰半胱氨酸后脂联素表达增高,脂联素受体1表达无改变。抵抗素和脂联素水平的降低是高脂饲养大鼠体重增加、血糖升高、脂质代谢紊乱和胰岛素抵抗的重要原因。NF-kB通路介导了脂联素对胰岛素敏感性的调节作用,但不影响脂联素受体1的表达。     

瑞舒伐他汀对高脂饲养大鼠心肌脂联素及其受体表达的影响

目的　探讨瑞舒伐他汀对高脂饲养大鼠心肌脂联素及其受体mRNA和蛋白表达的影响。方法　8周龄Wistar大鼠48只,随机分为对照组、高脂饲养组、高脂饲养＋瑞舒伐他汀组,20周后,全自动生化分析仪测定血清甘油三酯（TG）、总胆固醇（TC）、低密度脂蛋白胆固醇（LDLC）、高密度脂蛋白胆固醇（HDLC）、血糖,ELISA测定血清脂联素,RT-qPCR和　Western　blot测定心肌组织脂联素及其受体　mRNA和蛋白的表达。结果　与对照组相比,高脂饲养组大鼠血清TG、TC、LDLC、血糖、脂联素升高（P＜0.01）,HDLC降低（P＜0.01）。与高脂饲养组相比,高脂饲养＋瑞舒伐他汀组血清TG、TC、LDLC、脂联素降低（P＜0.05）,　HDLC升高（P＜0.01）,血糖无明显差异（P＞0.05）。与对照组相比,高脂饲养组心肌脂联素mRNA和蛋白表达升高（P＜0.01）,心肌脂联素受体mRNA和蛋白表达降低（P＜0.05）。与高脂饲养组相比,高脂饲养＋瑞舒伐他汀组心肌脂联素mRNA和蛋白表达降低（P＜0.05）,心肌脂联素受体1　mRNA和蛋白表达升高（P＜0.05）,心肌脂联素受体2　mRNA和蛋白表达无明显差异（P＞0.05）。结论　高脂饲养大鼠过程中,可出现血清脂联素升高,心肌脂联素mRNA和蛋白表达上调,心肌脂联素受体mRNA和蛋白表达下调,瑞舒伐他汀可以部分逆转这些作用。     

替米沙坦对非酒精性脂肪性肝炎大鼠血清脂联素、肝脏AdipoR2 mRNA表达及胰岛素抵抗的影响

目的探讨替米沙坦对非酒精性脂肪性肝炎大鼠胰岛素抵抗、血清脂联素及其肝组织脂联素受体R2mRNA表达的影响。方法 35只雄性SD大鼠随机分为正常对照组(NC,n=10)、模型组(FC,n=15)和替米沙坦干预组(FT,n=10)。FC和FT组给予高脂饲料喂养16周诱发脂肪性肝炎,其中FT组于高脂喂养12周后,给予替米沙坦(5mg·kg-1·d-1)灌胃治疗4周。检测血清ALT、AST、空腹血糖、空腹胰岛素和胰岛素抵抗指数(HOMA-IR);应用RT-PCR方法测定大鼠肝组织脂联素受体R2mRNA的表达;ELISA法测定血浆脂联素水平。结果与NC组相比,FC组脂联素及其受体R2mRNA水平均显著降低(P0.01);FT组的脂联素及其受体R2mRNA水平较FC组升高(P0.05)。脂联素及其受体R2mRNA水平均与HOMA-IR呈负相关(r分别为-0.891,-0.686;P0.01,0.05)。结论替米沙坦能上调脂联素及其受体R2的表达,改善非酒精性脂肪性肝炎大鼠的胰岛素抵抗。     

2型糖尿病患者皮下、大网膜脂肪组织脂联素mRNA表达的定量研究

目的　探讨 2型糖尿病患者皮下及大网膜脂肪组织脂联素 (adiponectin)表达水平及与血脂联素、体重指数、腰臀比 (WHR)、胰岛素敏感性的相关关系。方法　用实时荧光定量RT PCR检测 2型糖尿病患者和非糖尿病患者皮下及大网膜脂肪组织脂联素mRNA的表达水平 ,用ELISA方法测定血浆脂联素水平。结果　 2型糖尿病患者大网膜脂肪组织脂联素mRNA表达水平较非糖尿病组显著下降 (P <0 .0 5 ) ;糖尿病组与非糖尿病组的血浆脂联素水平差异无显著性 ;糖尿病组大网膜脂肪组织脂联素mRNA表达与WHR成负相关 (r=- 0 .5 1,P <0 .0 5 )。糖尿病组血浆脂联素水平与大网膜脂肪组织脂联素mRNA的表达成正相关 (r=0 .5 7,P <0 .0 1)。结论　 2型糖尿病患者大网膜脂肪组织脂联素mRNA表达显著降低。内脏脂肪组织脂联素mRNA的表达水平可以作为胰岛素抵抗的重要参数。     

重组人白介素6抑制SW872脂肪细胞脂联素及其受体1的表达和脂联素的分泌

油酸诱导体外培养的SW872前脂肪细胞分化为成熟的脂肪细胞，然后加入重组人白细胞介素6（rhIL-6）干预；RT—PCR方法检测脂联素、脂联素受体1和2mRNA水平，ELISA方法检测细胞培养上清中脂联素蛋白的含量。结果显示，rhIL-6以剂量和时间相关的方式抑制SW872脂肪细胞脂联素及其受体1mRNA的表达及脂联素的分泌，对脂联素受体2mRNA的表达无影响。     

肥胖和2型糖尿病患者脂肪组织脂联素mRNA表达的研究

用实时定量PCR技术检测2型糖尿病患者(肥胖与非肥胖)和非2型糖尿病者皮下及大网膜脂联素mRNA表达量;ELISA法测血清脂联素浓度。皮下脂肪脂联素mRNA表达量高于大网膜;2型糖尿病、肥胖患者大网膜脂肪脂联素mRNA表达量对血清脂联素浓度有影响;性别可影响脂联索mRNA表达。     

The effects of exercise and adipose tissue lipolysis on plasma adiponectin concentration and adiponectin receptor expression in human skeletal muscle

OBJECTIVE: It has been suggested that adiponectin regulates plasma free fatty acid (FFA) clearance by stimulating FFA uptake and/or oxidation in muscle. We aimed to determine changes in plasma adiponectin concentration and adiponectin receptor 1 and 2 mRNA expression in skeletal muscle during and after prolonged exercise under normal, fasting conditions (high FFA trial; HFA) and following pharmacological inhibition of adipose tissue lipolysis (low FFA trial; LFA). Furthermore, we aimed to detect and locate adiponectin in skeletal muscle tissue. METHODS: Ten subjects performed two exercise trials (120 min at 50% VO(2max)). Indirect calorimetry was used to determine total fat oxidation rate. Plasma samples were collected at rest, during exercise and during post-exercise recovery to determine adiponectin, FFA and glycerol concentrations. Muscle biopsies were taken to determine adiponectin protein and adiponectin receptor 1 and 2 mRNA expression and to localise intramyocellular adiponectin. RESULTS: Basal plasma adiponectin concentrations averaged 6.57+/-0.7 and 6.63+/-0.8 mg/l in the HFA and LFA trials respectively, and did not change significantly during or after exercise. In the LFA trial, plasma FFA concentrations and total fat oxidation rates were substantially reduced. However, plasma adiponectin and muscle adiponectin receptor 1 and 2 mRNA expression did not differ between trials. Immunohistochemical staining of muscle cross-sections showed the presence of adiponectin in the sarcolemma of individual muscle fibres and within the interfibrillar arterioles. CONCLUSION: Plasma adiponectin concentrations and adiponectin receptor 1 and 2 mRNA expression in muscle are not acutely regulated by changes in adipose tissue lipolysis and/or plasma FFA concentrations. Adiponectin is abundantly expressed in muscle, and, for the first time, it has been shown to be present in/on the sarcolemma of individual muscle fibres.     

厄贝沙坦对自发性高血压大鼠瘦素、脂联素的影响

目的 探讨血管紧张素Ⅱ受体拮抗剂（ARB）厄贝沙坦对自发性高血压大鼠（SHR）瘦素、脂联素的影响及可能机制.方法 24只雄性SHR大鼠随机分为SHR模型组（SHR-C）、SHR氢氯噻嗪组（SHR-H）和SHR厄贝沙坦组（SHR-I）,每组8只;另设同源雄性Wistar Kyoto（WKY）大鼠8只为对照组.SHR-I组应用厄贝沙坦30 mg·kg-1·d-1灌胃,SHR-H组应用氢氯噻嚷10 mg·kg-1·d-1灌胃,SHR-C和WKY组均配以等量蒸馏水灌胃,连续8周后,测尾动脉收缩压（SBP）;颈动脉取血,检测血清血糖、胰岛素、瘦素和脂联素浓度;取大鼠附睾脂肪组织,通过反转录和聚合酶链反应（RT-PCR）,分析附睾脂肪瘦素mRNA和脂联素mRNA表达水平.结果 与WKY组比较,SHR-C组大鼠收缩压显著升高（P＜0.01）;与SHR-C组比较,SHR-I组和SHR-H组大鼠收缩压显著降低（P＜0.01）.与WKY组比较,SHR-C组大鼠胰岛素抵抗指数（HOMA-IR）显著升高（P＜0.01）;与SHR-H组和SHR-C组比较,SHR-I组大鼠HOMA-IR明显降低（P＜0.05）.与WKY组比较,SHR-C组大鼠血清瘦素浓度和脂肪瘦素mRNA表达水平显著增高（P＜0.01）;与SHR-C组比较,SHR-I组大鼠血清瘦素浓度显著降低（P＜0.01）,脂肪瘦素mRNA表达水平明显降低（P＜0.05）.与WKY组比较,SHR-C组大鼠血清脂联素浓度和脂肪脂联素mRNA表达水平显著降低（P＜0.01）;与SHR-C组比较,SHR-I组大鼠血清脂联索浓度和脂肪脂联索mRNA表达水平显著升高（P＜0.01）.结论 厄贝沙坦能改善自发性高血压大鼠胰岛索的敏感性,减少其脂肪组织瘦素的合成和分泌,增加脂联素的合成和分泌.     

Effects of short-term exercise on adiponectin and adiponectin receptor levels in rats

AIM: Adiponectin reportedly reduces insulin resistance. Exercise has also been shown to lessen insulin resistance, although it is not well known whether exercise increases levels of adiponectin and/or its receptors nor whether it effects are dependent on exercise intensity and/or period. We previously reported that blood adiponectin levels increased by 150% in animals that exercised at a rate of 30 m/min for 60 minutes, 2 days per week, and adiponectin receptor 1 (AdipoR1) mRNA levels in muscle increased up to 4 times in response to exercise at a rate of 25 m/min for 30 min, 5 days per week for 12 weeks. METHODS: In light of this information, we examined the effects of short-term exercise on adiponectin, and adiponectin receptor levels in rats, using ELISA and real-time PCR. RESULTS: Our data showed that adiponectin mRNA levels in adipose tissue increased by 280% in rats exercised at a rate of 30 m/min for 60 minutes for 2 weeks and correlated with the exercise time periods. No effects of short-term exercise on adiponectin receptor 1 mRNA in muscle were observed. CONCLUSION: Thus, long-term exercise may be required to regulate adiponectin receptor 1 mRNA expression in muscle and adiponectin mRNA expression in adipose tissue.     

Changes in adiponectin receptor expression in muscle and adipose tissue of type 2 diabetic patients during rosiglitazone therapy

Aims/hypothesis Adiponectin is important in the regulation of insulin sensitivity in man. Its receptors, adipoR1 and R2, have recently been identified, but their expression in adipose tissue and their regulation in response to insulin sensitisation of diabetic patients have never been assessed. We therefore explored the regulation of adipoR1/R2 and adiponectin expression in adipose tissue and skeletal muscle, and of adiponectin plasma concentrations in response to insulin sensitisation by rosiglitazone.Methods Patients with type 2 diabetes were studied in a double-blind, placebo-controlled crossover study, using in vivo arteriovenous techniques of measuring adipose tissue and muscle blood flow, combined with measurement of adipose tissue and skeletal muscle gene expression.Results Rosiglitazone treatment increased adiponectin concentrations by 69%. Skeletal muscle adipoR1 expression was down-regulated from 109.0 (70.1–165.7) (median [interquartile range]) to 82.8 (63.6–89.3) relative units (p=0.04), but adipose tissue adipoR1 expression was up-regulated from 5.3 (4.4–9.4) to 11.2 (4.8–15.3) relative units (p=0.02) by rosiglitazone. In contrast to adipoR1 expression, adipoR2 expression was not altered by rosiglitazone in either of the tissues. The increase in adipose tissue adipoR1 expression with rosiglitazone was associated with increased postprandial triglyceride clearance (r=0.67, p=0.05), and increased fasting fatty acid output (r=0.78, p=0.01) measured in subcutaneous adipose tissue.Conclusions/interpretation AdipoR1 expression is up-regulated in adipose tissue but down-regulated in skeletal muscle by rosiglitazone. These data suggest that adipoR1 plays a role in mediating the effects of adiponectin in specific tissues in relation to insulin sensitisation.G. D. Tan, and C. Debard contributed equally to this work.     

Expression of the adiponectin receptors AdipoR1 and AdipoR2 in lean rats and in obese Zucker rats

The adiponectin receptors, AdipoR1 and AdipoR2, are thought to transmit the insulin-sensitizing effects of adiponectin, an adipokine secreted by adipocytes. Modifications of their expression in insulin-sensitive tissues (skeletal muscle, liver, and adipose tissue) could therefore play a role in the control of insulin sensitivity and the development of insulin resistance. Recent data in mice supported this possibility. We examined whether the expression of adiponectin receptors (messenger RNA [mRNA] concentrations) is controlled in vivo in rats (Wistar) by nutritional factors (high-fat [HF] vs high-carbohydrate diet, fasting vs fed state) and whether this expression is decreased in an experimental model of insulin resistance, the obese Zucker rat. In Wistar rats, neither an HF diet nor fasting modified the mRNA concentrations of AdipoR1 in muscle, liver, or adipose tissue; the only modification observed was a decrease (P < .05) in AdipoR2 mRNA level in the liver of rats fed with an HF diet. In obese Zucker rats compared with their lean controls, neither AdipoR1 nor AdipoR2 expression was modified in muscle. AdipoR2 expression was slightly decreased in adipose tissue, whereas the expression of both AdipoR1 and AdipoR2 was increased (P < .05) in the liver of obese Zucker rats. In conclusion, contrary to what was reported in mice, the expression of adiponectin receptors in rats is poorly responsive to changes in nutritional conditions and is not decreased in a model of insulin resistance. These results do not support an important role for the expression of AdipoR1 and AdipoR2 in the modulation of sensitivity to insulin.     

Upregulation of adiponectin receptor 1 and 2 mRNA and protein in adipose tissue and adipocytes in insulin-resistant women with polycystic ovary syndrome

Aims/hypothesis Polycystic ovary syndrome (PCOS) is a multifaceted metabolic disease linked with insulin resistance (IR) and obesity. Adiponectin, which is lower in IR states, exerts its glucose-lowering and anti-inflammatory effects by activating two receptors, ADIPOR1 and ADIPOR2. There are no data on the relative expression of these receptors in adipose tissue of PCOS women.Methods We investigated the expression of adiponectin receptors from corresponding s.c. and omental (o.m.) adipose tissue in women with PCOS compared with matched non-PCOS women. As there is a disturbance in the steroid milieu in PCOS women, we also assessed the effects of testosterone and oestradiol on adiponectin receptors using adipocytes and adipocyte explants. Real-time RT-PCR and western blotting were used to assess the relative adiponectin receptor mRNA expression and protein production, respectively. Biochemical measurements were performed in our hospital’s laboratory.Results We are the first to describe adiponectin receptor expression and production, in corresponding s.c. and o.m. human adipose tissues at the mRNA and protein level. We demonstrate the upregulation of mRNA expression and protein production of adiponectin receptors in women with PCOS, in s.c. and o.m. adipose tissue. Treatment of adipose tissue explants and adipocytes with testosterone and oestradiol induced the expression of adiponectin receptor mRNA and protein. There was a significant positive association between ADIPOR1/R2 expression and homeostasis model assessment, testosterone, oestradiol and triglycerides and a negative relationship with sex hormone-binding globulin.Conclusions/interpretation The precise reason for the upregulation of adiponectin receptors seen in PCOS women, a pro-diabetic state, is unknown, but it appears that sex steroids may play a role in their regulation in adipose tissue.Electronic supplementary material Supplementary material is available for this article at and is accessible to authorised users.B. K. Tan and J. Chen contributed equally to this work.     

替米沙坦上调内脏脂肪组织的脂联素表达并改善胰岛素抵抗

目的 探讨替米沙坦对体外原代培养的人前脂肪细胞和OLETF大鼠脂肪组织中脂联素表达以及胰岛素敏感性的影响.方法 提取人腹部皮下和内脏的前脂肪细胞,原代培养并传代后接种于无血清培养基,分为对照组（H-N）、吡格列酮组（H-P）和替米沙坦（H-T）组.葡萄糖消耗试验测定细胞的胰岛素敏感性,实时荧光定量PCR（RT-PCR）技术测定细胞脂联素mRNA的表达,放射免疫法测定培养基上清脂联素的分泌量.4周龄雄性OLETF大鼠28只,初始体重150～180 g.高脂喂养,分为对照组（O-HFD组,10只）、吡格列酮组（O-P组,8只）和替米沙坦组（O-T组,10只）.口服葡萄糖耐量实验和高胰岛素-正糖钳夹实验检测胰岛素抵抗指数和60 ～ 120 min葡萄糖输注速度以测定大鼠胰岛素抵抗水平,RT-PCR和Western blotting技术检测大鼠皮下和内脏脂肪组织脂联素的mRNA和蛋白表达.计量资料均数比较应用单因素方差分析.结果 H-T组和H-P组内脏前脂肪细胞的葡萄糖消耗量较之H-N组明显升高[分别为（5.6±1.6）、（4.4±1.6）、（2.0±0.8）mmol/L,F=20.240,P＜0.05].O-T和O-P组大鼠高胰岛素-正糖钳夹实验得到的60 ～ 120 min葡萄糖输注速度明显高于O-HFD组大鼠[分别为（18±5）、（20±4）、（10±3） mg·kg-1·min-1,F=8.136,P＜0.05].O-T和O-P组大鼠的HOMA胰岛素抵抗指数也显著低于O-HFD组大鼠（分别为10.0±8.6、5.5±2.0、17.8±10.1,F=5.784,P＜0.05）.替米沙坦可降低高脂饲养OLETF大鼠升高的腹围、内脏脂肪系数和血清游离脂肪酸水平,并改善大鼠的空腹高血糖,差别有统计学意义[分别为（24.0±2.0）比（26.5±2.7） cm、5.8％±2.4％比8.6％±2.4％、（2.8±0.7）比（5.3±1.8）μg/L、（10±6）比（15±7） mmoL/L,均P＜0.05].H-T较之H-N组原代培养人前脂肪细胞和O-T较之O-HFD组大鼠脂肪组织脂联素的mRNA表达和蛋白分泌量均明显上调（均P＜0.05）.H-T较之H-P组人内脏脂肪细胞和O-T较之O-P组大鼠内脏脂肪组织脂联素mRNA和蛋白表达水平均升高或有上升的趋势（分别为59.9±2.0比6.0±1.6、1.807±0.297比1.332±0.112、4.43±2.57比1.71±0.57、2.6±0.9比1.9±0.5,均P＜0.05）.结论 替米沙坦具有提高OLETF大鼠与人前脂肪细胞胰岛素敏感性、缓解大鼠的内脏性肥胖和改善大鼠糖脂代谢功能紊乱的作用,并很可能通过上调脂肪尤其是内脏脂肪的脂联素表达来完成.     

吡格列酮对2型糖尿病大鼠骨骼肌脂联素受体1表达的影响

目的观察吡格列酮对2型糖尿病大鼠血清脂联素以及骨骼肌脂联素受体1(AdipoR1)表达的影响,探讨吡格列酮对2型糖尿病胰岛素抵抗的改善作用及机制。方法 40只8周龄健康雌性SD大鼠,随机分为正常对照组(n=10)、糖尿病组(n=15)及吡格列酮组(n=15)。用高糖高脂饲料加小剂量链脲佐菌素建立2型糖尿病大鼠模型,成模后吡格列酮组给予10 mg/(kg.d)吡格列酮灌胃,正常对照组和糖尿病组给予同体积生理盐水灌胃,共12周。3个月后股静脉取血,酶联免疫吸附法(ELISA)测定血清脂联素水平,留取大鼠骨骼肌,光、电镜观察骨骼肌结构,免疫组织化学染色法测定骨骼肌AdipoR1蛋白的表达。结果与正常对照组(1.73±0.32 mg/L)比较,糖尿病组血清脂联素(1.01±0.27 mg/L)水平显著降低,而吡格列酮组(1.34±0.43 mg/L)较糖尿病组显著升高,差异有统计学意义(P<0.05)。骨骼肌AdipoR1免疫组织化学染色正常对照组着色深且广泛,糖尿病组较正常对照组染色浅,吡格列酮组较糖尿病组染色深,但较正常对照组浅。光镜及电镜结果显示大鼠骨骼肌结构未见明显异常。结论 2型糖尿病大鼠血清脂联素水平及骨骼肌AdipoR1表达降低并导致糖脂代谢紊乱及胰岛素抵抗。吡格列酮可上调血清脂联素及骨骼肌AdipoR1的表达,从而调节糖脂代谢,改善胰岛素抵抗。